The multiple sclerosis therapy alemtuzumab–marketed in the United States as Lemtrada –may trigger severe, unpredictable adverse effects, according to German researchers. Writing in Lancet Neurology , the scientists report on two patients in whom the infusion of alemtuzumab significantly worsened symptoms.